These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16260906)

  • 41. Decline in the AIDS and death rates in the EuroSIDA study: an observational study.
    Mocroft A; Ledergerber B; Katlama C; Kirk O; Reiss P; d'Arminio Monforte A; Knysz B; Dietrich M; Phillips AN; Lundgren JD;
    Lancet; 2003 Jul; 362(9377):22-9. PubMed ID: 12853195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improvement of HAART in Brazil, 1998-2008: a nationwide assessment of survival times after AIDS diagnosis among men who have sex with men.
    Malta M; da Silva CM; Magnanini MM; Wirtz AL; Perissé AR; Beyrer C; Strathdee SA; Bastos FI
    BMC Public Health; 2015 Mar; 15():226. PubMed ID: 25886530
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.
    Lima VD; Hogg RS; Harrigan PR; Moore D; Yip B; Wood E; Montaner JS
    AIDS; 2007 Mar; 21(6):685-92. PubMed ID: 17413689
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy.
    Shelburne SA; Visnegarwala F; Darcourt J; Graviss EA; Giordano TP; White AC; Hamill RJ
    AIDS; 2005 Mar; 19(4):399-406. PubMed ID: 15750393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
    Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy.
    Sabin CA; Yee TT; Devereux H; Griffioen A; Loveday C; Phillips AN; Lee CA
    AIDS; 2000 May; 14(8):1001-7. PubMed ID: 10853982
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics of untreated AIDS-related cytomegalovirus retinitis. II. Findings in the era of highly active antiretroviral therapy (1997 to 2000).
    Holland GN; Vaudaux JD; Shiramizu KM; Yu F; Goldenberg DT; Gupta A; Carlson M; Read RW; Novack RD; Kuppermann BD;
    Am J Ophthalmol; 2008 Jan; 145(1):12-22. PubMed ID: 18154751
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women.
    Ahdieh-Grant L; Li R; Levine AM; Massad LS; Strickler HD; Minkoff H; Moxley M; Palefsky J; Sacks H; Burk RD; Gange SJ
    J Natl Cancer Inst; 2004 Jul; 96(14):1070-6. PubMed ID: 15265968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
    Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
    AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Morbidity after antiretroviral therapy initiation in HIV-1-infected children in West Africa: temporal trends and relation to CD4 count.
    De Beaudrap P; Boullé C; Lewden C; Gabillard D; Nacro B; Diagbouga S; Fassinou P; Hien H; Laurent C; Msellati P;
    Pediatr Infect Dis J; 2013 Apr; 32(4):354-60. PubMed ID: 23099424
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients.
    Palella FJ; Chmiel JS; Moorman AC; Holmberg SD;
    AIDS; 2002 Aug; 16(12):1617-26. PubMed ID: 12172083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
    Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
    PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study.
    Mitchell SM; Membrey WL; Youle MS; Obi A; Worrell S; Gazzard BG
    Br J Ophthalmol; 1999 Jun; 83(6):652-5. PubMed ID: 10340970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
    Rouet F; Fassinou P; Inwoley A; Anaky MF; Kouakoussui A; Rouzioux C; Blanche S; Msellati P;
    AIDS; 2006 Nov; 20(18):2315-9. PubMed ID: 17117017
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.